Morgan Stanley (MS)

202.42
+0.00 (0.00%)
NYSE· Last Trade: Sep 17th, 6:19 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.fool.com
Income investors shouldn't be too worried about the pharma giant cutting its dividend.
Via The Motley Fool · September 17, 2026
Eaton Sees Best Years Ahead as Data Center Demand Powers Growthmarketbeat.com
Eaton (NYSE:ETN) Chief Executive Officer Paulo Ruiz told investors at Morgan Stanley’s Laguna Conference that the company’s strategy is gaining momentum, supported by strong electrical-market demand, manufacturing capacity additions and a portfolio increasingly focused on data centers and aerospace.
Via MarketBeat · September 17, 2026
The Fed Hikes, Warsh Says Nothing Else, and Wall Street Fills In the Blankschartmill.com
Via Chartmill · September 17, 2026
Why J.B. Hunt Stock Dropped Todayfool.com
J.B. Hunt shares dropped more than 13% after CFO Brad Delco told a Morgan Stanley investor conference that Q3 earnings would fall 5% to 10% from Q2.
Via The Motley Fool · September 16, 2026
The Fed Hiked Interest Rates for the First Time in 3 Years. Are AI Stocks in Trouble?fool.com
Capital costs could rise alongside rising interest rates.
Via The Motley Fool · September 16, 2026
Freeport-McMoRan Eyes Leach Breakthrough, Bagdad Growth and Grasberg Recoverymarketbeat.com
Freeport-McMoRan (NYSE:FCX) is pursuing growth through U.S. brownfield expansions, technology investments and the recovery of its Grasberg mine in Indonesia, President and CEO Kathleen Quirk said during a Morgan Stanley conference discussion. Quirk said copper remains the company’s central focus as
Via MarketBeat · September 16, 2026
GEV Stock Jumps After GE Vernova CEO Touts This Milestoneinvestors.com
GE Vernova chief spoke of "strong and durable demand," as backlog grows.
Via Investor's Business Daily · September 16, 2026
GE Vernova (GEV) Stock Is Up, What You Need To Know
What Happened? Shares of energy transition company GE Vernova (NYSE:GEV) jumped 4.5% in the afternoon session after the company projected strong backlog grow...
Via StockStory · September 16, 2026
Boeing Eyes MAX 10 Certification as 737 Ramp, 777X Tests and Labor Vote Loommarketbeat.com
Boeing (NYSE:BA) executives said the company has made progress on commercial production, aircraft certification and defense-program execution, while continuing to work through supply-chain constraints, inventory levels and potential labor disruption. Speaking at a Morgan Stanley event, President an
Via MarketBeat · September 16, 2026
Boeing Stock Skids As CEO Warns Of Further 737 Production Delaysinvestors.com
Boeing stock fell as much as 6% on Wednesday.
Via Investor's Business Daily · September 16, 2026
QuantumScape Ramps Pilot Line as Solid-State Battery Markets Expandmarketbeat.com
QuantumScape (NYSE:QS) is focusing on ramping its automated pilot production line as it seeks to commercialize solid-state lithium-metal batteries for automotive customers and newly identified markets including data centers, aerospace, defense, robotics, consumer electronics and medical devices. Sp
Via MarketBeat · September 16, 2026
The Dow, S&P 500, and Nasdaq Split Ahead of a Near-Certain Rate Hikefool.com
The Fed is about to raise rates for the first time in three years. The dot plot matters more.
Via The Motley Fool · September 16, 2026
American Airlines Sees Strong Demand, but Fuel Spike Threatens Profit Outlookmarketbeat.com
American Airlines Group (NASDAQ:AAL) CEO Robert Isom said demand remains strong across the carrier’s network, cabins and geographies, while volatile fuel costs remain the principal constraint on profitability. Speaking at a Morgan Stanley conference, Isom said American expects third-quarter revenue
Via MarketBeat · September 16, 2026
S&P 500 Trucking Stock Craters On CFO's Warninginvestors.com
J.B. Hunt warned of lower Q3 earnings amid surging fuel costs and higher yields.
Via Investor's Business Daily · September 16, 2026
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipelinemarketbeat.com
GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre
Via MarketBeat · September 16, 2026
One Wall Street Analyst Just Said Tesla Stock Could Be Worth $840: Time to Buy?fool.com
The analyst update is not particularly significant on its own, but it helps highlight a Tesla business that deserves more attention.
Via The Motley Fool · September 16, 2026
Morgan Stanley Sees Wealth, AI Financing and Deal Rebound Powering Growthmarketbeat.com
Morgan Stanley (NYSE:MS) Co-President Dan Simkowitz said the firm does not view 2026 as a peak-earnings year, citing growth opportunities in wealth management, a developing capital-markets recovery and continued financing demand tied to artificial intelligence. Speaking at an investor conference, S
Via MarketBeat · September 16, 2026
Honeywell Sees Strong Start as Pure-Play Automation Push Gains Momentummarketbeat.com
Honeywell International (NASDAQ:HON) Chairman and CEO Vimal Kapur said the company is seeing stronger-than-expected early-quarter momentum as it begins operating as a more focused automation business following the completed spins of its aerospace and advanced materials operations. Speaking at a Mor
Via MarketBeat · September 16, 2026
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Prioritiesmarketbeat.com
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou
Via MarketBeat · September 16, 2026
Rivian Calls R2 Launch an Inflection Point as Demand, Autonomy Plans Acceleratemarketbeat.com
Rivian Automotive (NASDAQ:RIVN) is entering what founder and CEO RJ Scaringe described as an “inflection point year,” as the electric-vehicle maker begins scaling its R2 midsize SUV and expands its software, autonomy and licensing initiatives. Speaking at a Morgan Stanley event, Scaringe said the R
Via MarketBeat · September 15, 2026
RTX Highlights $289B Backlog as Aerospace, Defense Demand Powers Growthmarketbeat.com
RTX (NYSE:RTX) Chairman, President and CEO Chris Calio said the aerospace and defense company remains positioned to benefit from sustained commercial aviation and defense demand, citing a $289 billion backlog that was up 22% from a year earlier. Speaking at a Morgan Stanley aerospace and defense co
Via MarketBeat · September 15, 2026
Medtronic Sees AI, Ablation and Targeted M&A Fueling Growthmarketbeat.com
Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum. Speaking with Peter Harrison of Morgan Stanley Investment Bankin
Via MarketBeat · September 15, 2026
General Motors Sees Q3 on Track as Truck Launch, Digital Growth Fuel 2027 Outlookmarketbeat.com
General Motors (NYSE:GM) Chief Financial Officer Paul Jacobson said the automaker’s business is tracking consistently with its expectations for the third quarter, supported by resilient consumer demand, disciplined inventory management and production running near maximum levels across its system. S
Via MarketBeat · September 15, 2026
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advancesmarketbeat.com
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.” Speaking
Via MarketBeat · September 15, 2026
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipelinemarketbeat.com
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E
Via MarketBeat · September 15, 2026